120
Participants
Start Date
July 27, 2022
Primary Completion Date
November 13, 2025
Study Completion Date
November 13, 2025
Pembrolizumab
200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)
Coformulation favezelimab/pembrolizumab
800 mg favezelimab + 200 mg pembrolizumab administered via IV infusion on day 1 and then Q3W
MK-4830
800 mg administered via IV infusion Q3W
Lenvatinib
20 mg administered via oral capsules each day
Irinotecan
180 mg/m\^2 administered via IV infusion on day 1 of every 14-day cycle.
Paclitaxel
80-100 mg/m\^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle
Taipei Veterans General Hospital ( Site 2005), Taipei
Chang Gung Medical Foundation-Linkou Branch ( Site 2006), Taoyuan District
Taichung Veterans General Hospital-Radiation Oncology ( Site 2008), Taichung
National Cheng Kung University Hospital ( Site 2001), Tainan City
Hôpitaux Universitaires de Genève (HUG) ( Site 2702), Geneva
Kantonsspital Graubünden-Medizin ( Site 2700), Chur
National Taiwan University Hospital ( Site 2000), Taipei
Chulalongkorn University ( Site 2104), Bangkok
Faculty of Medicine Siriraj Hospital ( Site 2102), Bangkok
Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 2804), Berlin
Ospedale San Raffaele-Oncologia Medica ( Site 1206), Milan
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1200), Milan
Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (, Milan
Atatürk Üniversitesi-onkoloji ( Site 1416), Erzurum
Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 1104), Brest
Acibadem Altunizade Hospital-Oncology ( Site 1407), Üsküdar / İstanbul
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1403), Istanbul
Istituto Oncologico Veneto IRCCS ( Site 1205), Padua
Universitaetsklinikum Duesseldorf ( Site 2802), Düsseldorf
Hopital Claude Huriez - CHU de Lille ( Site 1100), Lille
Institut für Klinisch Onkologische Forschung-Klink für Onkologie und Hämatologie ( Site 2801), Frankfurt am Main
Pitie Salpetriere University Hospital ( Site 1102), Paris
Chang Gung Memorial Hospital at Kaohsiung ( Site 2003), Kaohsiung Niao Sung Dist
Songklanagarind hospital ( Site 2105), Hat Yai
National University Hospital ( Site 1800), Singapore
China Medical University Hospital ( Site 2007), Taichung
FALP-UIDO ( Site 2400), Santiago
Clínica las Condes ( Site 2403), Santiago
Liga Norte Riograndense Contra o Câncer ( Site 2303), Natal
Hospital Nossa Senhora da Conceição ( Site 2301), Porto Alegre
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300), São Paulo
Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 2806), Dresden
Aichi Cancer Center Hospital ( Site 1702), Nagoya
National Cancer Center Hospital East ( Site 1701), Kashiwa
Saitama Prefectural Cancer Center ( Site 1703), Ina-machi
Shizuoka Cancer Center ( Site 1704), Nagaizumi-cho,Sunto-gun
National Cancer Center Hospital ( Site 1700), Chuo-ku
Oslo universitetssykehus, Radiumhospitalet ( Site 2501), Oslo
Asan Medical Center-Department of Oncology ( Site 1901), Seoul
Samsung Medical Center-Division of Hematology/Oncology ( Site 1900), Seoul
I.E.U. Medical Point Hastanesi-Oncology ( Site 1406), Izmir, Karsiyaka
Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 1417), Adana
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1402), Ankara
Memorial Ankara Hastanesi-Medical Oncology ( Site 1408), Ankara
Ankara City Hospital-Medical Oncology ( Site 1405), Ankara
Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 1410), Antalya
Merck Sharp & Dohme LLC
INDUSTRY